Citation Impact
Citing Papers
Liver function tests and fibrosis scores in a rural population in Africa: a cross-sectional study to estimate the burden of disease and associated risk factors
2020
Nonalcoholic fatty liver associated with impairment of kidney function in nondiabetes population.
2012
Mechanisms of hepatic stellate cell activation
2017 Standout
Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Risk in Obese Children and Adolescents
2012
Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease
2012
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
2017 Standout
Relationship between Kidney Function and Liver Histology in Subjects with Nonalcoholic Steatohepatitis
2010
Novel adipokines vaspin and irisin as risk biomarkers for cardiovascular diseases in type 2 diabetes mellitus
2018
Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics
2014 Standout
Local and systemic effects of the multifaceted epicardial adipose tissue depot
2015
Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease
2014
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
2012
Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link?
2010
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
2016 Standout
Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?
2012
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
2020
Non-alcoholic fatty liver disease
2021 Standout
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
CKD and Nonalcoholic Fatty Liver Disease
2014
Global burden of liver disease: 2023 update
2023 Standout
Endocrine fibroblast growth factors 15/19 and 21: from feast to famine
2012
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
2016 Standout
What We Talk About When We Talk About Fat
2014 Standout
Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
2014
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
Extrahepatic complications of nonalcoholic fatty liver disease
2013
Nonalcoholic steatohepatitis and increased risk of chronic kidney disease
2010
Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications
2016
Increased risk of cardiovascular disease and chronic kidney disease in NAFLD
2012
NAFLD: A multisystem disease
2015 Standout
Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease
2016
MECHANISMS IN ENDOCRINOLOGY: Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21
2012
Heritability of non‐alcoholic fatty liver disease and association with abnormal vascular parameters: A twin study
2012
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
The Fibroblast Growth Factor signaling pathway
2015 Standout
Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
2015
Circulating Levels of FGF-21 in Obese Youth: Associations With Liver Fat Content and Markers of Liver Damage
2013
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
2013
Association of Vaspin with Metabolic Syndrome: The Pivotal Role of Insulin Resistance
2014
Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in J apanese patients (LEAN ‐J )
2014
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Fibroblast Growth Factor 21—Metabolic Role in Mice and Men
2017
Pathophysiology of Type 2 Diabetes Mellitus
2020 Standout
Thyroid Hormone Regulation of Metabolism
2014 Standout
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
2017 Standout
Understanding the Physiology of FGF21
2015
Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease
2011
Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection
2013
Works of Oya Yönal being referenced
NONINVASIVE ASSESSMENT OF LIVER FIBROSIS WITH THE ASPARTATE TRANSAMINASE TO PLATELET RATIO INDEX (APRI): USEFULNESS IN PATIENTS WITH CHRONIC LIVER DISEASE
2011
Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease
2010
Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis
2010
Circulating Levels of Vascular Endothelial Growth Factor A and Its Soluble Receptor in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease
2011
Serum galectin-3 levels in patients with nonalcoholic fatty liver disease
2011
Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: Association with liver fibrosis
2010
Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease
2010
Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease
2011
Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease
2010
S1862 Microalbuminuria in Nondiabetic Patients With Nonalcoholic Fatty Liver Disease: Association With Liver Fibrosis
2010
Serum Progranulin as an Independent Marker of Liver Fibrosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease
2011
Serum progranulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease.
2011
Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis.
2012
877 SERUM LEVELS OF OMENTIN, CHEMERIN AND ADIPSIN IN PATIENTS WITH BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE
2011
Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease.
2011